Blood Podcast Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance
Jun 5, 2025
Dive into the fascinating world of leukemia stem cells as researchers use single-cell multi-omics to identify unique subpopulations, paving the way for new treatments. Discover how cyclophosphamide can alleviate non-immune neurotoxicities in CAR T-cell therapy patients, stressing the need for prompt management. Also, explore the intriguing effects of glycosylation on von Willebrand factor half-life, comparing recombinant and plasma-derived options and their impact on future therapies. Science and a glimpse into innovative treatments await!
AI Snips
Chapters
Transcript
Episode notes
Leukemia Stem Cells Drive Resistance
- Leukemia stem cells with HSPC-like properties drive chemotherapy resistance and poor outcomes.
- Targeting FLT3, BCL2, and PI3K pathways shows promise against these cells.
Early Cyclophosphamide for NINTS
- Use cyclophosphamide early to treat NINTS after BCMA CAR T-cell therapy for better response.
- Monitor closely for infectious complications following cyclophosphamide treatment.
Glycosylation Extends VWF Half-Life
- Enhanced α2,3-linked sialylation in recombinant VWF extends its half-life by reducing receptor binding and clearance.
- Glycan engineering can improve therapeutic protein stability and efficacy.